PHARMACOEPIDEMIOLOGY : A REVIEW
DOI:
https://doi.org/10.22270/ajprd.v7i2.464Keywords:
Pharmacoepidemiology, epidemiology, drug utilizationAbstract
Pharmacoepidemiology is the study of the use of drugs in a large number of people.It is a growing discipline that applies epidemiological techniques to study drugs used in a large population. Just as the term implies, pharmacoepidemiology combines clinical pharmacology with epidemiology. Pharmacology is the study of the effects of medications on humans; it pertains to using pharmacokinetic and pharmacodynamic parameters of patients to predict the effect of drugs. Epidemiology, on the other hand, is the study of the factors that determine the occurrence and distribution of diseases in a population. In its broad concept, it encompasses drug utilization studies, and identification and quantification of adverse drug reactions (ADRs); its aim is to improve the quality and use of medicines. Drug utilization studies are known to involve the marketing, distribution, prescription, and use of drugs in a society with special emphasis on the medical, social, and economic consequences. The discipline, when not considered sufficiently, has a potential that could cause a high-level of increase in health expenses by creating conflict in the health systems of countries. In this study, it is aimed to define pharmacoepidemiology, to analyze its relation with other disciplines and to inform about pharmacoepidemiology usage areas.
Downloads
References
2. Lawson D.H. Pharmacoepidemiology: A New Discipline, British Medical Journal, 1984; 289(6450):940-941.
3. Etminan M, Samii A.. Pharmacoepidemiology I: A Review of Pharmacoepidemiologic Study Designs. Pharmacotherapy, 2004; 24(8):964–969.
4. Bergman U. Pharmaco-epidemiological perspectives, Pharmaceutical Weekblad, 11(5), 1989, 151-4.
5. Briggs AH, Levy AR. Pharmacoeconomics and Pharmacoepidemiology: Curious Bedfellows or a Match Made in Heaven, Pharmacoeconomics, 2006; 24(11):1079-1086.
6. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP), Pharmacoepidemiology and Drug Safety, 2005; 14:589–595.
7. Law MT. How do Regulators Regulate? Enforcement of the Pure Food and Drugs Act, 1907–38, The Journal of Law, Economics & Organization, 2000; 22(2):459-489.
8. Botting J. The History of Thalidomide. Drug News Perspect, 2002;15(9):604.
9. Collier J. Paediatric Prescribing: Using Unlicensed Drugs and Medicines Outside Their Licensed Indications, British Journal of Clinical Pharmacology, 1999; 48(1):5-8.
10. Drug Lag by Daniel Henninger,http://www.econlib.org/library/Enc1/DrugLag.html
11. Wardell WM. The drug lag revisited: comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976, Clinical Pharmacology & Therapeutics, 1978; 24:499-524.
12. Bhaven CK, Mehta D, Mehta S. Drug Lag for Antimicrobial Agents: Comparison of the USA. Europe and India Approvals, National Journal of Medical Research, 2012; 2(3): 264-268.
13. Boston Collaborative Drug Surveillance Program, BCDSP – Pharmacoepidemiology and Drug Safety Research, http://www.bu.edu/bcdsp
14. Avorn J. The Role of Pharmacoepidemiology and Pharmacoeconomics in Promoting Access and Stimulating Innovation, Pharmacoeconomics, 2004; 22(2):81-86.
15. Jones JK. Pharmacogenetics and Pharmacoepidemiology, Pharmacoepidemiology and Drug Safety, 2001; 10(5):457–461.
16. Waller P. Pharmacoepidemiology-A Tool for Public Health, Pharmacoepidemiology and Drug Safety, 2001; 10(2): 165–172.
17. Lee JAH, Draper PA, Weatherall M.. Prescribing in Three English Towns, Milbank Memorial Fund - The Milbank Quarterly, 1965.
18. Muller C, Outpatient drug prescribing by general practice. British Medical Journal, 1968; 1: 671-674.
19. Routledge PA. Adverse drug reactions and interactions: mechanisms, risk factors, detection, management and prevention, in J Talbot, P Waller (Ed.), Stephens' Detection of New Adverse Drug Reactions, 4 (John Wiley & Sons Ltd, 2004).
20. HA Guess. Premarketing Applications of Pharmacoepidemiology, In Pharmacoepidemiology, in BL Strom (Ed.), Wiley-Blackwell, 4, 2005.
21. A Acar, S. Yeğenoğlu, Sağlık Ekonomisi, Perspektifinden Farmakoekonomi, Hacettepe University, Journal of the Faculty of Pharmacy, 2006; 26(1):39-55.
22. Pinar Yalcin Balcik, Gulcan Kahraman. Pharmacoepidemiology, IOSR Journal Of Pharmacy, 2016; 6(2):57-62
23. Jones JK. Pharmacogenetics and Pharmacoepidemiology, Pharmacoepidemiology and Drug Safety, 2001; 10(5):457–461
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.